Search PubMed⌕ Search

Biomedical subjects

R Lenzhofer

Publications and source records attributed to R Lenzhofer.

45 records · Page 3Linked to original sources
PubMed1980

[Developments in the serological diagnosis of malignant diseases].

The present study gives an evaluation of carcinoembryonic antigen (CEA), macrophage electrophoretic mobility test (MEM), sialyltransferase, galactosyltransferase isoenzyme (SGT), ribonuclease and reverse transcriptase as diagnostic aids in malignant diseases. CEA and sialyltransferase are of certain value in the monitoring of cancer, as their values in the serum may rise before progression of disease or relapse. Both tests are not reliable parameters in the early diagnosis of malignancy. Our results with regard to the MEM test have not proved in any way useful in the diagnosis of cancer. Our preliminary results appear to indicate that, provided further simplification of the method can be achieved, SGT isoenzyme determination seems to be a better means of diagnosing cancer. In view of inherent-methodological difficulties reverse transcriptase has, at present, no clinical application in the diagnosis of cancer.

Carcinoembryonic Antigen↗
PubMed1980

[Haemodynamic effects after application of nitroglycerin sublingually or as ointment in patients with left ventricular heart failure (author's transl)].

The haemodynamic effects of a 2% nitroglycerin ointment and of sublingual nitroglycerin in patients with left ventricular heart failure were investigated. The well-known pulmonary blood pressure and pulmonary wedge-pressure lowering effect were observed with both forms of administration. Differences exist between onset and duration of the haemodynamic effects. With sublingual administration of nitroglycerin the peak effect was seen after 5 minutes, whilst the pulmonary blood pressure rose again 30 minutes later. After application of nitroglycerin ointment a peak effect was seen 30 minutes later and the effects were sustained for 3 to 6 hours.

Administration, Oral↗
PubMed1980

Methotrexate-citrovorum factor used alone and in combination chemotherapy for advanced hypernephromas.

Methotrexate-citrovorum factor (MTX-CF) therapy was administered to 20 patients with advanced renal cell carcinoma. Eight patients were treated with MTX-CF only. Two patients who received short-term rescue showed partial remissions along with severe toxicity including gastrointestinal symptoms and bone marrow depression. Twelve patients were treated with a combination of MTX-CF, vincristine, bleomycin, and an alkylating agent (either peptichemio or cyclophosphamide). In this latter group, patients with a glomerular filtration rate of greater than 70 ml/minute received 150-400 mg/m2/cycle of MTX. Patients with decreased renal function (less than 70 ml/minute) received 35-100 mg/m2/cycle of MTX. Two of seven patients with a decreased glomerular filtration rate showed partial remissions and four patients had static disease. One patient in the group of five with normal renal function showed static disease. None showed objective improvement. The median survival time was 25 months for patients with partial remission and static disease and 4.75 months for patients with progression. This difference is highly significant (P less than 0.0005). These results seem to justify further investigations of MTX-CF therapy in hypernephromas, even in the presence of impaired renal function.

Adenocarcinoma↗
PubMed1979

[Course and intensive treatment of acute falciparum malaria (author's transl)].

The case of a nineteen-year-old women with the cerebral form of malaria tropica is reported. She showed hyperpyrexia, abdominal manifestations, haemolysis and disseminated intravascular coagulation. Cerebral symptoms amounting to grade IV encephalopathy occurred. The patient responded rapidly to the administration of chloroquine, anticonvulsants, dextran, corticosteroids, antipyretics, blood and antithrombin III and her symptoms had almost completely vanished one week after the onset of therapy.

Acute Disease↗
PubMed1979

[Results and pharmacokinetic aspects of methotrexate therapy in high doses].

We used MTX as single drug treatment on the basis of an incremental dosage schedule, with doses increased from 250 mg/m2 to 750 mg/m2 or from 5 to 10 g, at intervals of 10 days. Moderately high MTX doses (750 mg/m2 at most) plus citrovorum factor rescue, failed to result in objective tumor regression in all of the 18 patients thus treated. High-dose MTX with CF rescue, by contrast, was found to produce partial remissions in 3 of the 19 cases treated thus far. Meticulous clinical monitoring and MTX serum level determinations are imperative for minimizing complications, if this drastic treatment regimen is employed.

Dose-Response Relationship, Drug↗
PubMed1977

[Thyroid function following thyroidectomy determined by the TRH-induced release of thyrotropin (author's transl)].

The response of hTSH to TRH (400 mug i.v.) was studied in 45 patients who underwent thyroid surgery for various reasons. Euthyroid values of T4 and ETI were observed in all but one patient. An increased response of hTSH to TRH (as compared with 15 control subjects) was observed in 12 out of 30 patients operated upon for non-toxic goitre, in one out of nine operated upon for toxic goitre and in three out of six patients who underwent thyroidectomy for thyroid carcinoma or proliferating adenoma of the thyroid. The necessity of specific replacement therapy in those individuals with increased release of hTSH upon TRH administration is discussed.

Adult↗
PubMedDate not supplied

Neuroleptanalgesia in acute myocardial infarction: effects of hemodynamic parameters and plasma catecholamines.

The use of neuroleptanalgesia in acute myocardial infarction offers the possibility of reducing pain and emotional stress. The influence of such treatment on hemodynamic parameters (heart rate, cardiac output, stroke volume, peripheral resistance, systemic blood pressure, and pulmonary pressure) and on the plasma level of adrenaline and noradrenaline has been studied in 6 patients with acute myocardial infarction. This results demonstrate that during neuroleptanalgesia the already elevated levels of noradrenaline and adrenaline further increase. This increase was most pronounced in the patients with the highest initial levels of catecholamines. Since the peripheral resistance and systolic and diastolic blood pressures decrease concomitantly, it is concluded that the increase in levels of noradrenaline and adrenaline further increase. This increase was most pronounced in the plasma catecholamines is due to a reaction of the sympathetic nervous system to the alpha-adrenergic receptor blocking activity of droperidol causing vasodilation. The data indicate that pain, emotional stress, and anxiety in the acute phase of myocardial infarction do not play the expected essential role for the activation of the sympathetic nervous system generally observed in acute myocardial infarction. Additionally, the data demonstrate that drugs producing a vasodilation can have a deteriorating effect on the hemodynamic situation and that a reduction of the afterload by vasodilating drugs can result in a further increase in the release of catecholamines.

Aged↗